Poster und Publikationen
2022
Kresken M, Pfeifer Y, Wagenlehner F, Werner G, Wohlfarth E; on behalf of Study Group ‘Antimicrobial Resistance‘ of the Paul Ehrlich Society for Infection Therapy. Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20. Antibiotics 2022, 11, 751. https://doi.org/10.3390/antibiotics11060751
Lâm TT, Wohlfarth E, Claus H, Vogel C, Kresken M. Antibiotic resistance in Haemophilus influenzae isolates obtained from patients at outpatient departments in Germany, 2019/2020. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Oral Session OF094, Abstract 537, Talk O0394
Link
Kresken M, Gatermann SG, Higgins PG, Pfeifer Y, Pfennigwerth N, Seifert H, Werner G, Wohlfarth E. Comparative in-vitro activity of cefiderocol and four newer β-lactam/β-lactamase inhibitor combinations against two panels of clinically important Gramnegative pathogens from Germany. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Poster Session PS018, Abstract 629, Poster P0599
Link
Kresken M, Wohlfarth E, Pfeifer Y, Werner G. Multidrug-resistance to oral antibiotics among Escherichia coli urine isolates from patients at outpatient departments in Germany and in vitro activity of nitroxoline, Germany, 2010-2019. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Poster Session PS018, Abstract 584, Poster P0684
Link
Kresken M, Pfeifer Y, Wagenlehner F, Werner G, Wohlfarth E. Resistance to mecillinam and nine other antibiotics for oral use in Escherichia coli isolated from urine specimens of primary care patients in Germany, 2019/2020. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Poster Session PS018, Abstract 526, Poster P0685
Link
Kresken M, Wohlfarth E, Weikel C, Butler D, Pfeifer Y, Werner G. In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Poster Session PS018, Abstract 60, Poster P0686
Link
2021
Kresken M, Klare I, Wichelhaus TA, Wohlfarth E, Layer-Nicolaou F, Neumann B, Werner G; Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility. J Glob Antimicrob Resist. 2022 Mar;28:102-107. doi: 10.1016/j.jgar.2021.12.016.
Kresken M, Klare I, Wichelhaus TA, Wohlfarth E, Layer-Nicolaou F, Neumann B, Werner G; Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalized patients in Germany: occurrence, characteristics, and susceptibility to dalbavancin. J Glob Antimicrob Resist. 2021 Dec 24:S2213-7165(21)00289-7. https://doi.org/10.1016/j.jgar.2021.12.016
Kresken M, Korte-Berwanger M, Pfennigwerth N, Gatermann SG. In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany. J Global Antimicrob Resist. 2021;25: 337–338
2020
Werner G, Neumann B, Weber RE, Kresken M, Wendt C, Bender JK. The VRE study group. Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci. Drug Resist Updat 53 (2020) 100732
Gröschel MI, Meehan CJ, Barilar I, Diricks M, Gonzaga A, Steglich M, Conchillo-Solé O, Scherer IC, Mamat U, Luz CF, De Bruyne K, Utpatel C, Yero D, Gibert I, Daura X, Kampmeier S, Rahman NA, Kresken M, van der Werf TS, Alio I, Streit WR, Zhou K, Schwartz T, Rossen JWA, Farhat MR, Schaible UE, Nübel U, Rupp J, Steinmann J, Niemann S, Kohl TA. The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia. Nat Commun. 2020 Apr 27;11(1):2044. doi: 10.1038/s41467-020-15123-0.
2019:
M. Kresken, P. G Higgins, D. Stefanik , J. Wille, B. Körber-Irrgang, H. Seifert
The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany, 2010 -2016. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 13-16, 2019, P0922
M. Kresken, Y. Pfeifer, J. Bender, B. Körber-Irrgang, G. Werner
Extended-spectrum-beta-lactamase (ESBL)-producing strains among clinical isolates of
Escherichia coli and Klebsiella pneumoniae from hospitalized patients in Germany, 2010 -2016. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 13-16, 2019, P1209
M. Kresken, Y. Pfeifer, J. Bender, B. Körber-Irrgang, G. Werner
Dissemination of extended-spectrum beta-lactamase genes and resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany, 2010 -2016. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 13-16, 2019, P1619
M. Kresken, F.Layer, B. Körber-Irrgang, G. Werner
Prevalence, antibiotic resistance patterns and spa types of MRSA from hospitalised patients in Germany, 2010-2016. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 13-16, 2019, P2699
2018:
M. Kresken, B. Körber-Irrgang; Ergebnisse der PEG Resistenzstudie 2016 - Resistenzsituation im stationären Versorgungsbereich
Poster
M. Kresken, B. Körber-Irrgang; Ergebnisse der PEG Resistenzstudie 2016 – Resistenzsituation bei Escherichia coli Urinisolaten gegenüber oral applizierbaren Antibiotika im ambulanten Versorgungsbereich
2017:
Olzowy B, Kresken M, Havel M, Hafner D, Körber-Irrgang B; Working Party Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Antimicrobial susceptibility of bacterial isolates from patients presenting with ear, nose and throat (ENT) infections in the German community healthcare setting. Eur J Clin Microbiol Infect Dis (2017) 36:1685–1690. DOI 10.1007/s10096-017-2985-9.
2016:
Körber-Irrgang B, Pfeifer Y, Werner G, Kresken M. In vitro Aktivität von Cefoxitin gegenüber ESBL-produzierenden Escherichia-coli- und Klebsiella-pneumoniae-Isolaten aus dem Hospitalbereich. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 25.
Körber-Irrgang B, Pfeifer Y, Werner G, Kresken M, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. ESBL-Bildung und Fluorchinolon-Resistenz bei Escherichia-coli- und Klebsiella-pneumoniae-Isolaten aus dem Hospitalbereich. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 10.Poster
Kresken M, Olzowy B, Havel M, Hafner D, Körber-Irrgang B, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Antibiotika-Empfindlichkeit bakterieller Erreger von Patienten mit HNO-Infektionen in der ambulanten Versorgung - Ergebnisse der PEG-Resistenzstudie 2013 und deren klinische Bedeutung. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 11.
Körber-Irrgang B, Kresken M, Kniehl E, Becker A, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Epidemiologie und Antibiotika-Empfindlichkeit multiresistenter Gram-negativer (MRGN) Blutkulturisolate in Deutschland - Ergebnisse der Blutkulturstudie im Rahmen der PEG-Resistenzstudie 2013/14. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 12.
Kresken M, Körber-Irrgang B, Hafner D für die Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie. Verbreitung von multiresistenten Escherichia-coli-Urinisolaten in der ambulanten Patientenversorgung und In-vitro-Aktivität von Nitroxolin: Ergebnisse der PEG-Resistenzstudie 2013. 13. KIT, Würzburg, 15. - 18. Juni 2016: P-117.
Körber-Irrgang B, von Müller L, Westenberger J, Hafner D, Herrmann M, Kresken M, and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. In vitro activity of fidaxomicin and comparators against Clostridium difficile isolates obtained from community and hospitalized patients: results of the PEG study. 13. KIT, Würzburg, 15. - 18. Juni 2016: eP-009.
Kresken M, Körber-Irrgang B, Hafner D, and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. Multidrug resistance to oral antibiotics in Escherichia coli urine isolates from outpatients in Germany and in vitro activity of nitroxoline: results of the PEG 2013 study. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P0077.
Kresken M, Körber-Irrgang B, Hafner D, Kaase M, Pfeifer Y, Layer F, Klare I, Werner G, Seifert H, and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. Prevalence of multidrug resistance among bacterial pathogens obtained from patients in hospitals and the role of tigecycline: results of the PEG 2013 study. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P0326.
Körber-Irrgang B, von Müller M, Westenberger J, Hafner D, Herrmann M, Kresken M and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. Comparative susceptibilities of Clostridium difficile isolates to fidaxomicin obtained from community and hospitalized patients: results of the PEG 2013 study. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P0615.
Poster und Publikationen von 2015-1996 finden Sie hier.